Background: This study was conducted to evaluate whether smoking history and the standardized uptake value (SUV) of 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG) uptake are associated with unexpected pathological N2 status (pN2) in non-small-cell lung cancer (NSCLC).
introduction
Patients with early stages of non-small-cell lung cancer (NSCLC) can only achieve long-term survival with surgery. Although surgical exploration can be carried out in patients with clinical N2 stage [1] , the results are disappointing [2] . Thus, accurate clinical staging is paramount in decision of surgical treatment in patients with NSCLC.
Noninvasive staging of mediastinal nodes in patients with NSCLC is challenging. With the introduction of 2-[fluorine-18]fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET), an improved accuracy of nodal staging has been documented compared with the use of computed tomography (CT) alone [3, 4] . Generally, positive mediastinal findings on FDG-PET or CT require further confirmation with invasive modalities [4] . Although a high negative predictive value of PET with respect to N2 nodes has been reported [3, 5] , false-negative findings of PET or CT may lead to unnecessary surgery in patients with advanced disease. Specifically, in normal-sized nodes, clinical judgment on negative PET findings is questionable [6, 7] .
Increasing evidence suggests unique clinicopathological features of never smokers [8, 9] . In addition to predominant female gender and adenocarinomas [9, 10] , a high frequency of advanced stage in never smokers compared with ever smokers has been reported [10] [11] [12] . Although PET findings according to smoking history has not been established, in our previous data [13] we observed that never smokers show a low standardized uptake value (SUV) of primary tumors compared with ever smokers.
Using noninvasive methods, prediction of pathological N2 status (pN2) in clinical N2-negative NSCLC may help physicians to select patients for further invasive staging. Along with the possible role of SUV of primary tumors for nodal stage [14, 15] , recent data on smoking history and its association with disease extent [10] [11] [12] led us to consider the impact of smoking history and SUV for unexpected pN2. Thus, we retrospectively analyzed PET findings and smoking status for pN2 in resected NSCLC patients who were preoperatively diagnosed with negative N2 nodes.
methods patients and methods
We analyzed clinical data of patients with NSCLCs who underwent resection with curative intent between January 2005 and December 2009 at the Korea Cancer Center Hospital in Seoul. Preoperative staging included bronchoscopy, brain imaging, chest and upper abdominal CT, and PET-CT. We excluded 11 patients who had a history of malignancy within 5 years, or were treated with preoperative chemotherapy or chemoradiotherapy. Information on smoking history was retrospectively gathered from medical record. One radiologist and two nuclear medicine physicians interpreted CT and PET-CT images, respectively. After careful review of the CT and PET-CT scans, localizations of lymph nodes to show an enlarged size or avid FDG uptake were recorded using the American Thoracic Society lymph node classification system [16] . A tumor was considered to be central when it is located in the inner one-third of the lung field, and peripheral otherwise [17] . Locoregional lymph nodes were considered positive if the short diameter of discrete nodes was >1 cm or the FDG accumulation intensity was definitely above the surrounding background activity, with a consensus of the two nuclear medicine physicians. Fifty-nine patients were classified into positive N2 on CT or PET-CT. Excluding these patients, 220 patients were defined as N2 negative on CT and PET-CT.
At the time of surgical exploration, lymph node dissections were routinely carried out with evaluation of at least four N2 stations according to the drainage pattern. Lymph nodes were labeled and sent for pathological examination. Sections of 3-4 mm were taken and nodal metastases determined histologically following hematoxylin and eosin staining. The mean number (6 standard deviation) of removed N2 nodes was 19.8 (69.9) per patient. We obtained exemption of the Institutional Review Board at the Korea Cancer Center Hospital for this retrospective study.
FDG-PET-CT imaging
Whole-body FDG-PET-CT scans were carried out during staging work-ups using the acquisition protocol previously described [13] . The FDG-PET-CT scan data were acquired in two-or three-dimensional mode by means of one of two PET-CT scanners: Discovery LS PET/CT scanner (GE Medical Systems, Waukesha, WI), 124 patients, or Biograph 6-Hirez PET/ CT scanner (Siemens Medical Systems, Knoxville, TN), 96 patients. Patients underwent PET-CT scan 50 min after the i.v. injection of 370 MBq of FDG. Whole-body images of CT and PET were obtained in sequence. PET data acquired in three-dimensional mode were transformed to two-dimensional formatted data using Fourier rebinning before the generation of tomographic images. PET images were reconstructed using the twodimensional ordered-subset expectation maximization algorithm (2 iterations/16 subsets for the Discovery LS and 2 iterations/8 subsets for the Biograph) incorporating a CT-based attenuation correction.
We manually drew regions of interest (ROIs) around the area of primary tumor showing avid FDG uptake on transaxial sections of the PET images, with the anatomical information from CT images [13] . The highest voxel value in the ROIs covering the region of primary tumor was selected to determine the maximum SUV of the primary tumor.
statistical analysis
Univariate analysis of categorical variables was carried out using Pearson's chi-square test and Fisher's exact test. Comparison of continuous variables according to pN2 was carried out using the Kruskal-Wallis test. Stepwise backward logistic regression analysis was used to construct the fitted model including independent significant factors for pN2. Tumor location could not enter an initial step for logistic analysis due to a relatively limited number of observations. We used Hosmer-Lemeshow goodness-of-fit chi-square tests to assess model fit. Odds ratios (ORs) and the 95% confidence intervals (CIs) were determined. Receiver operating characteristic (ROC) curves for SUV to predict pN2 were analyzed. A fitted ROC curve was constructed using a binominal model. To avoid a possible bias of partial volume effect [18] , tumors <1.5 cm on CT were excluded when analysis included SUV as a variable. Stata (version 9.0; Stata Corp., College Station, TX) was used for statistical analyses. P values from two-sided tests <0.05 were considered significant.
results patient characteristics
Data from 220 patients are summarized in Table 1 . The median age was 66 years and 69% of the patients were men. Forty-nine percent of patients had adenocarcinomas and 72 patients (33%) had never smoked. The primary tumors clinical features associated with pN2
Unexpected pN2 was detected in 34 patients (15%). Associations between clinical features and pN2 were evaluated; the results are listed in Table 2 . Based on univariate analysis, adenocarcinomas (P = 0.019), female gender (P = 0.010), N1 on CT (P = 0.025), and N1 on PET-CT (P = 0.001) were associated with a high probability of pN2. The proportion of pN2 in never smokers was higher than in ever smokers (26% versus 10%, respectively; P = 0.002). Age, tumor size, and T stage on CT were not related with pN2. Univariate analysis did not show different incidences of pN2 according to the SUV of the primary tumor as a continuous variable. However, based on multivariate analysis, SUV remained a significant factor for pN2 (OR 1.1; 95% CI 1.0-1.2; P = 0.010). In addition, never smokers (P = 0.007), adenocarcinomas (P = 0.044), and N1 stage on PET-CT (P = 0.001) were more likely to have pN2. N1 on CT was excluded as a redundant variable.
SUV of primary tumors according to smoking history
After we observed more frequent pN2 in never smokers, image findings were analyzed according to smoking history. The tumor size of never smokers (median 2.6 cm; range 1.0-6.0 cm) was smaller compared with that of ever smokers (P = 0.001; median 3.2 cm; range, 1.0-8.1 cm). In addition, the SUV of never smokers (median 6.0; range 1.2-24.0) was lower than that of ever smokers (P < 0.001; median 10.9; range 1.0-29.0). Next, we attempted to analyze a predictive role of the SUV of primary tumors according to smoking history. ROC analysis of SUV with respect to pN2 was carried out (Figure 1 ). The area under curve (AUC) of the SUV was increased in never smokers compared with ever smokers (AUC 0.75 in never smokers; 95% CI 0.63-0.87 versus AUC 0.53 in ever smokers; 95% CI 0.40-0.66), suggesting different significance of SUV according to smoking history (P = 0.017). Given the difference of SUV according to smoking history, we dichotomized tumors ‡1.5 cm in diameter into low and high subsets using each median value (6.0 for never smokers and 10.9 for ever smokers). In 68 never smokers, the proportion of pN2 was significantly higher in patients with high SUV compared with those with a low SUV (79% and 21%, respectively; P = 0.002). However, in 141 ever smokers, there was no difference in proportion of pN2 between OR, odds ratio; CI, confidence interval; NI, not included; CT, computed tomography; PET, positron emission tomography; SUV, standardized uptake value.
original article Annals of Oncology tumors with high and low SUV (10% and 11%, respectively; P = 0.852).
discussion
We evaluated clinical significance of smoking status and PET-CT findings on unexpected pN2 in patients with NSCLC. In addition to histology and N1 on PET-CT, smoking history and the SUV of primary tumors were associated with the prevalence of pN2. Interestingly, a high SUV of primary tumors could predict unexpected pN2 in never smokers. However, in smokers, an association between the SUV and pN2 was not suggested. In this study we focused on smoking history and the association with unexpected pN2. The more frequent pN2 in never smokers in this study was partly supported by previous data to show a high proportion of advanced stage in never smokers [10] [11] [12] . Although further molecular studies for unexpected tumor spread in never smokers need to follow, the plausible explanation for this result is that small tumor size and low FDG uptake by tumors in never smokers may lead to difficulty in detecting occult metastases to N2 nodes. Importantly, in clinical setting of mediastinal staging, a high probability of unexpected pN2 in never smokers may justify physicians' attention not to avoid invasive staging simply based on their favorable outcomes [10, 11] .
Our data suggest the different usages of SUV of primary tumors according to smoking history. We observed pN2 and its association with the SUV of primary tumors, along with adenocarcinoma and N1 on PET-CT, as reported in other studies [5, 14, 15, 19, 20] . Interestingly, further analysis revealed that the SUV of primary tumors in never smokers could predict pN2, whereas that of ever smokers could not. In clinical practice, this finding is important because PET findings to predict unexpected pN2 might lead to further aggressive strategies in selected patients.
It should be stressed that the current study has been undertaken in an Asian population. The proportion of never smokers (33%) in our study appears to be high compared with that in Western studies, as suggested in previous studies [12, 21] . Although a prior study has reported a lack of an association between smoking history and stage in a limited population [22] , recent large-scale studies suggest a more common presentation of advanced stage in never smokers compared with ever smokers [10] [11] [12] . Thus, it is possible that a different prevalence of never smokers may affect stage distribution across diverse ethnicities, as suggested in a previous study [11] . Theoretically, in consideration of our findings suggesting small tumor size and low FDG uptake in never smokers, a relatively low sensitivity of PET-CT might be expected in Asian studies [23, 24] compared with Western studies [3, 5, 25] . However, a different role of PET for N2 staging by ethnicity and smoking history needs to be elucidated by large-scale studies over diverse ethnic groups.
As suggested in other studies [19, 20] , the independent predictive value of N1 status on PET-CT regarding pN2 was observed, whereas that of N1 on CT was not noted. The use of integrated PET-CT, compared with PET, may lead to improved discrimination of nodal metastases [26] . This indicates the usefulness of an additional consideration of metabolic staging to morphological staging [26, 27] . In contrast to prior studies [14, 20] , tumor location was not related to pN2 in our study. However, a lack of association between tumor location and pN2 was suggested in other studies using PET-CT scan [17, 19] . Considering the different findings of prior studies [14, 20] , the significance of tumor location alone appears to be unclear. Further studies need to follow.
In addition to the retrospective nature of the current study, several points can be addressed. First, because it is well known that FDG uptake can differ by each instrument [28] , we cannot exclude data distortion caused by different devices. However, when the type of PET-CT scanners were included, significant factors in the final model were not changed. Furthermore, when the phantom study was carried out, we observed similar quantitative measurements between two the PET-CT scanners [13] . Thus, patients' characteristics are more likely to affect the results of our analysis than variation of SUV according to devices. Secondly, universal use of SUV is limited because various factors including devices and protocols in each institution can affect it [28] . However, it should be stressed that the dose-response relationship, which could be assessed in any given institution using its PET protocol, between the probability of pN2 and SUV has been observed in never smokers. Thirdly, because this study was carried out in a limited population of operated cases, the different role of PET according to smoking story should be tested in a prospective manner. This is the first study to suggest an association between smoking history and mediastinal staging in clinically negative N2 NSCLC. We also observed the different significance of FDG uptake according to smoking history. This finding adds new insight to understanding nodal spread of tumors in never 
